The FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for patients with certain types of B-cell lymphoma.
The approval applies to adults with previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma who have an International Prognostic Index score of two or greater.
Polatuzumab vedotin-piiq (Polivy, Genentech) — an antibody-drug conjugate — targets CD79b on the surface of malignant B cells. The FDA granted the agent accelerated approval in June 2019